3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Skin Neoplasms
1
Neoplasms
1
Carcinoma, Merkel Cell
1
Carcinoma, Basal Cell
1
Carcinoma
1
Interventions
pembrolizumab
78
Cyclophosphamide
55
Specimen Handling
53
Carboplatin
49
fludarabine
44
Nivolumab
42
Magnetic Resonance Spectroscopy
42
Gemcitabine
37
Biopsy
37
Bevacizumab
34
Dexamethasone
31
venetoclax
27
Paclitaxel
26
Injections
25
Docetaxel
25
atezolizumab
24
Cisplatin
24
Pemetrexed
23
Ipilimumab
22
Capecitabine
21
Temozolomide
19
abemaciclib
18
Rituximab
18
Oxaliplatin
18
Lenalidomide
18
Fulvestrant
18
Cetuximab
18
Azacitidine
17
Vincristine
15
Fluorouracil
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
MAPRE1 protein, human
×
90 days
×
Clear all
NCT04349436
2026-04-22
ARTACUS
Replimune, Inc.
Phase 1/2
Active not recruiting
69 enrolled